AC Immune reports 12-month interim data from ACI-24 Alzheimer's trial

June 30, 2026 7:00 AM

AC Immune SA (NASDAQ: ACIU) announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found